World Obesity Federation, World Obesity Atlas; 2023. https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023 [Last accessed: January 12, 2024].
2.
FosterNC, BeckRW, MillerKM, et al.State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther, 2019; 21:66–72.
3.
RyanB, PeterC, GargSK. Weight gain and glycemic control in adults with type 1 diabetes in the T1D exchange registry. Diabetes Technol Ther, 2024; 26:156–160.
4.
American Diabetes Association Professional Practice Committee. Standards of care in diabetes. Diabetes Care, 2024; 47(Suppl. 1):S145–S157; doi: 10.2337/dc24-S008.
5.
GargSK, HenryRR, BanksP, et al.Effects of sotagliflozin added to insulin in type 1 diabetes. N Engl J Med, 2017; 377(24):2337–2348.
6.
ZinmanB, WannerC, LachinJM, et al.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015; 373(22):2117–2128.
7.
MarsoSP, BainSC, ConsoliA, et al.Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2016; 375:1834–1844.
8.
EdelmanSV, GargSK, FriasJP, et al.A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care, 2006; 29:2189–2195.
9.
FDA Approves New Drug Treatment (semaglutide for Chronic Weight Management), First Since 2014. Available from: FDA.Gov [Last accessed: January 10, 2024].
10.
GLP-1 drug Zepbound (tirzepatide) explained: New obesity treatment approved by FDA: November 2023. Available from: FDA.Gov [Last accessed: January 12, 2024].
11.
GargSK, KaurG, HaiderZ, et al.Efficacy of semaglutide in overweight and obese patients with type 1 diabetes. Diabetes Technol Ther, 2024; 26(3):184–189.
12.
GargSK, AkturkHK, KaurG, BeatsonC, Snell-BergeonJ. Safety and efficacy of tirzepatide in overweight and obese patients with type 1 diabetes. Diabetes Technol Ther, 2024; 26(6):367–374.
13.
Abbott announcement for continuous ketone monitor availability in 2024: ADA Scientific sessions, New Orleans, 2022. Close Concerns June 2022.
14.
SodhiM, RaminR, KezouhA, EtminanM. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA, 2023; 330(18):1795–1797; doi: 10.1001/jama.2023.19574.
15.
OlsenB. A weight-loss drug changed my life. Will it solve my problem? Wall Street J, 2024; [Last accessed: January 16, 2024].
